摘要
目的对比阿托伐他汀与瑞舒伐他汀对冠心病的治疗效果。方法方便选取该院2014年1月—2016年1月诊治的冠心病患者200例,分为阿托伐他汀组(A组)以及瑞舒伐他汀组(B组),A组服用阿托伐他汀进行诊治,B组服用瑞舒伐他汀进行诊治。在诊治前、诊治后半年以及诊治后1年在早上空腹时抽取静脉血,之后检测其血脂、三酰甘油等指标。结果 A组血清总胆固醇治疗前为(5.94±0.55)mmol/L,6个月后为(4.66±0.44)mmol/L,12个月为(4.00±0.48)mmol/L;B组血清总胆固醇治疗前为(6.09±0.49)mmol/L,6个月后为(5.15±0.48)mmol/L,12个月后为(4.76±0.42)mmol/L;B组三酰甘油、同型半胱氨酸指标优于A组,差异有统计学意义,P<0.05。结论瑞舒伐他汀比阿托伐他汀在治疗冠心病的效果上来看结果更加显著。
Objective To compare the therapeutic effect of atorvastatin and atorvastatin on coronary heart disease. Methods Convenient selection from January 2014 to January 2016, 200 patients with coronary heart disease in our hospital were divided into atorvastatin group（group A） and B group（B group）, A group were treated with atorvastatin, and the treatment group was treated with atorvastatin. Before the diagnosis and treatment, the second half of the year, as well as 1 years after the diagnosis and treatment of venous blood in the morning fasting, after testing their blood lipids, renal function and other indicators. Results The serum total cholesterol A group before treatment was（5.94±0.55） mmol/L, 6 months after the（4.66 ±0.44） mmol/L, 12 months（4±0.48） mmol/L; serum total cholesterol B group before treatment was（6.09 ±0.49） mmol/L, 6months after the（5.15±0.48） mmol/L, 12 months（4.76±0.42） mmol/L; B group of three glycerol, homocysteine and other indicators better than the A group, the difference was statistically significant. Conclusion The effect of atorvastatin in the treatment of coronary heart disease is more significant.
出处
《中外医疗》
2016年第33期140-141,144,共3页
China & Foreign Medical Treatment
关键词
阿托伐他汀
瑞舒伐他汀
冠心病
Atovatatin
Rosuvastatin
Coronary heart disease
